Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN003 Combination Therapy in HER2+ Gastric Cancer
NCT06998771Phase 2Not yet recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of anbenitamab repodatecan in gastric cancer (GC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
anbenitamab repodatecan
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06998771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06998771.